FLAG-Ida regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} IDA-FLAG Regimen; Idarubicin-Fludarabine-AraC/G-CSF Regimen ==Overview== {{PAGENAME}} refers to idarubicin, fludarabin...") |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to [[idarubicin]], [[fludarabine]], high-dose [[cytarabine|cytarabine (AraC)]] and [[filgrastim]] ([[G-CSF]]), used as a remission-induction treatment for for the treatment of poor-risk [[myelodysplastic syndromes]] and [[acute myeloid leukaemia]].<ref name="pmid9432047">{{cite journal| author=Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM et al.| title=Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. | journal=Br J Haematol | year= 1997 | volume= 99 | issue= 4 | pages= 939-44 | pmid=9432047 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9432047 }} </ref> | {{PAGENAME}} refers to [[idarubicin]], [[fludarabine]], high-dose [[cytarabine|cytarabine (AraC)]] and [[filgrastim]] ([[G-CSF]]), used as a remission-induction treatment for for the treatment of poor-risk [[myelodysplastic syndromes]] and [[acute myeloid leukaemia]].<ref name="pmid9432047">{{cite journal| author=Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM et al.| title=Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. | journal=Br J Haematol | year= 1997 | volume= 99 | issue= 4 | pages= 939-44 | pmid=9432047 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9432047 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|IDA|Idarubicin}} | {{chemo|IDA|Idarubicin}} | ||
| Line 22: | Line 20: | ||
==Indications== | ==Indications== | ||
*Poor-risk [[myelodysplastic syndromes]] and [[acute myeloid leukaemia]].<ref name="pmid9432047">{{cite journal| author=Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM et al.| title=Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. | journal=Br J Haematol | year= 1997 | volume= 99 | issue= 4 | pages= 939-44 | pmid=9432047 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9432047 }} </ref> | *Poor-risk [[myelodysplastic syndromes]] and [[acute myeloid leukaemia]].<ref name="pmid9432047">{{cite journal| author=Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM et al.| title=Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. | journal=Br J Haematol | year= 1997 | volume= 99 | issue= 4 | pages= 939-44 | pmid=9432047 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9432047 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
Latest revision as of 20:16, 17 March 2015
|
WikiDoc Resources for FLAG-Ida regimen |
|
Articles |
|---|
|
Most recent articles on FLAG-Ida regimen Most cited articles on FLAG-Ida regimen |
|
Media |
|
Powerpoint slides on FLAG-Ida regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on FLAG-Ida regimen at Clinical Trials.gov Trial results on FLAG-Ida regimen Clinical Trials on FLAG-Ida regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FLAG-Ida regimen NICE Guidance on FLAG-Ida regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on FLAG-Ida regimen Discussion groups on FLAG-Ida regimen Patient Handouts on FLAG-Ida regimen Directions to Hospitals Treating FLAG-Ida regimen Risk calculators and risk factors for FLAG-Ida regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for FLAG-Ida regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: IDA-FLAG Regimen; Idarubicin-Fludarabine-AraC/G-CSF Regimen
Overview
FLAG-Ida regimen refers to idarubicin, fludarabine, high-dose cytarabine (AraC) and filgrastim (G-CSF), used as a remission-induction treatment for for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.[1]
Regimen
IDAIdarubicin
FLFludarabine
ACytarabine (AraC)
GFilgrastim (G-CSF)
Indications
- Poor-risk myelodysplastic syndromes and acute myeloid leukaemia.[1]
References
- ↑ 1.0 1.1 Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM; et al. (1997). "Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia". Br J Haematol. 99 (4): 939–44. PMID 9432047.